TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25466662
Drug: Nutritional supplements
Normalized name: nutritional supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional supplements and rehabilitation program
Study: 23315099
Drug: Palliative chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palliative chemotherapy with CA 19-9, CEA, CRP, LDH, and bilirubin levels assessed before treatment and during treatment (for CA 19-9 only)
Study: 23315099
Drug: Pre-treatment CA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-treatment CA 19-9 levels
Study: 23315099
Drug: Pre-treatment LDH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-treatment LDH levels
Study: 23315099
Drug: Pre-treatment CEA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-treatment CEA levels
Study: 23315099
Drug: CA 19-9
Normalized name: CA-19-9 antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: CA 19-9 decline of ≥25% during the first two chemotherapy cycles
Study: 19744201
Drug: Chin bone
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chin bone augmentation
Study: 17094382
Drug: Sequential anthracycline-docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sequential anthracycline-docetaxel regimen
Study: 17094382
Drug: Standard chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard chemotherapy with anthracyclines
Study: 15087630
Drug: Gabapentin 1200
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gabapentin 1200 mg preoperatively
Study: 3135737
Drug: Thrombolytic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolytic therapy (timing before or after 4 hours of AMI onset)
Study: 3135737
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with patent arteries 90 minutes after therapy initiation
Study: 24469138
Drug: Nitrous oxide/oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrous oxide/oxygen inhalation sedation
Study: 24469138
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no nitrous oxide/oxygen inhalation sedation)
Study: 22311406
Drug: Feitai Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Feitai Capsule (1.2 g/capsule, 4 capsules, 3 times a day for 3 weeks, followed by 1 week off, continued for at least 3 more cycles, totaling 12 weeks)
Study: 15960643
Drug: 0.3 ml.kg(‐1)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 ml.kg(‐1) bupivacaine 0.25% plus 1 microg.kg(‐1) clonidine
Study: 12580705
Drug: Premarin (conjugated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Premarin (conjugated equine estrogen) 0.625 mg/d
Study: 12580705
Drug: Premarin (conjugated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Premarin (conjugated equine estrogen) 1.25 mg/d
Study: 14674906
Drug: Oral activated
Normalized name: activated charcoal Oral Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral activated charcoal
Study: 312366
Drug: Methylprednisolone (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone (500 mg added to each liter of cardioplegic solution)
Study: 12006932
Drug: HspE7 (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: HspE7 (500 microg monthly for 3 months)
Study: 29481992
Drug: Silicate-based wound
Normalized name: silicic acid
DrugBank: Silicic acid (DB14138)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silicate-based wound dressing (DermFactor®) combined with conventional dressing therapy
Study: 29481992
Drug: Conventional dressing
Normalized name: DRESSING
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional dressing therapy
Study: 20370447
Drug: Unfractioned Heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unfractioned Heparin (UFH)
Study: 18597921
Drug: Gonadotropin-releasing hormone
Normalized name: Gonadotropin-releasing hormone
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gonadotropin-releasing hormone agonist (GnRHa)
Study: 16634346
Drug: Weekly re-evaluation
Normalized name: Re-Covr
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly re-evaluation
Study: 11054359
Drug: Vancomycin (1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vancomycin (1,000 mg IV, 12 hours before procedure)
Study: 11054359
Drug: Cefazolin (1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefazolin (1,000 mg IV, 3 hours before procedure)
Study: 8844478
Drug: 0.3 MIU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 MIU IFN, administered twice per week for 24 weeks
Study: 8844478
Drug: 1 MIU
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 MIU IFN, administered twice per week for 24 weeks
Study: 8844478
Drug: 3 MIU
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3 MIU IFN, administered twice per week for 24 weeks
Study: 21414131
Drug: Titanium-13Zirconium (TiZr)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Titanium-13Zirconium (TiZr) implants
Study: 21414131
Drug: Titanium Grade
Approvals — FDA: no, EMA: no, PMDA: no
Description: Titanium Grade IV implants
Study: 20205166
Drug: Calcium intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium intake of 629 to 1835 mg/day
Study: 20205166
Drug: Calcium intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium intake of 648 mg/day (boys)
Study: 20205166
Drug: Calcium intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium intake of 666 mg/day (girls)
Study: 20205166
Drug: Calcium absorption
Normalized name: Evening Primrose Oil Oral Capsule, Liquid Filled [CALCIUM ABSORPTION FOR WOMEN]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium absorption and bone turnover rates measured using double-stable calcium isotope kinetic analysis
Study: 20205166
Drug: Calcium intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium intake of 1100 mg/day (boys)
Study: 20205166
Drug: Calcium intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium intake of 970 mg/day (girls)
Study: 17912118
Drug: Poly(L‐lactide‐co‐glycolide) osteofixation
Normalized name: poly (lactide-co-glycolide)-polyethylene glycol nanoparticles encapsulating quercetin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Poly(L‐lactide‐co‐glycolide) osteofixation
Study: 16047154
Drug: Verum (homeopathic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verum (homeopathic treatment) for 6 weeks
Study: 16047154
Drug: Long-term follow-up
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term follow-up after treatment
Study: 12452075
Drug: Midazolam (0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (0.05 mg/kg) with atropine (0.5 mg)
Study: 12452075
Drug: Phenobarbital sodium
Normalized name: Phenobarbital Sodium
DrugBank: Phenobarbital (DB01174)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenobarbital sodium (2 mg/kg) with atropine
Study: 2266671
Drug: Insulin with
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin with glucose
Study: 2266671
Drug: Combined regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined regimen of insulin with glucose and albuterol
Study: 17716826
Drug: Erythropoietin (Epo)
Normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythropoietin (Epo) 40,000 U once weekly, starting 7-10 days before radiotherapy
Study: 12040280
Drug: Combined chemoradiotherapy
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined chemoradiotherapy (induction chemotherapy with cisplatin, etoposide, and vinblastine followed by radiotherapy)
Study: 1962593
Drug: Droloxifene (new
Approvals — FDA: no, EMA: no, PMDA: no
Description: Droloxifene (new antiestrogenic drug)
Study: 1962593
Drug: Droloxifene (film-coated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Droloxifene (film-coated tablet, tablet, and standard solution)
Study: 6759056
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg tiaprofenic acid daily for 1 week
Study: 21336631
Drug: RelyX Unicem
Normalized name: Hippeastrum puniceum whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: RelyX Unicem combined with Gluma Desensitizer (RXU‐G)
Study: 21336631
Drug: G‐Cem combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐Cem combined with Gluma Desensitizer (GCM‐G)
Study: 21336631
Drug: Panavia21 combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Panavia21 combined with Gluma Desensitizer (PAN‐G)
Study: 19233485
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate nasal spray (MFNS) 100 microg once daily, n=166
Study: 15178656
Drug: 800 micro
Normalized name: Fentanyl 800 microgram buccal film
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 micro g of moistened (2 ml of saline) or dry vaginal misoprostol
Study: 11965505
Drug: Fenfluramine (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenfluramine (60 mg) once daily with energy restriction of -2.9 MJ/day (-700 kcal/day) for 15 weeks
Study: 11965505
Drug: Placebo once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo once daily with energy restriction of -2.9 MJ/day (-700 kcal/day) for 15 weeks
Study: 9781722
Drug: Surfactant (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surfactant (30 mg/kg) administered by intrabronchial instillation
Study: 8162664
Drug: Ranitidine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (300 mg four times a day)
Study: 362821
Drug: Formulation A
Normalized name: meningococcal vaccine of unknown formulation and unknown serogroups
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulation A (Tegretol)
Study: 362821
Drug: Formulation B
Normalized name: Hep B, unspecified formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulation B (Neurotol)
Study: 362821
Drug: Experimental preparations
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental preparations C and D
Study: 31100038
Drug: Nivolumab 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab 3 mg/kg (NIVO3)
Study: 31100038
Drug: Nivolumab 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab 3 mg/kg plus Ipilimumab 1 mg/kg (NIVO3+IPI1)
Study: 31100038
Drug: Nivolumab 1
Normalized name: nivolumab 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab 1 mg/kg plus Ipilimumab 3 mg/kg (NIVO1+IPI3)
Study: 26995376
Drug: Exenatide once‐weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exenatide once‐weekly 2 mg
Study: 17711927
Drug: BW-ADAPTED-T3T4 (combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: BW-ADAPTED-T3T4 (combination of T3 and T4 at a ratio of 1:10)
Study: 10546333
Drug: Oral exposure
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral exposure to one of the shapes for 90 seconds prior to visual stimuli testing (Experiment 1)
Study: 7481021
Drug: Propofol (sleep
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (sleep doses and N2O)
Study: 7481021
Drug: Propofol (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (10 mg/kg/h intravenous perfusion)
Study: 7481021
Drug: Dehydrobenzylperidol (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dehydrobenzylperidol (90 micrograms/kg) i.m. followed by sleep doses of propofol
Study: 1980654
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid (UDCA) 600 mg/day
Study: 25621791
Drug: Clonidine (α2‐adrenergic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (α2‐adrenergic agonist)
Study: 8848515
Drug: Scopolamine (muscarinic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scopolamine (muscarinic antagonist)
Study: 15190052
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of vitamins and minerals (200 mg Mg and 30 mg Zn + 200 mg vitamin C and 150 mg vitamin E)
Study: 15190052
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C and E (200 mg vitamin C and 150 mg vitamin E)
Study: 15190052
Drug: Mg and
Normalized name: Vraylar 1.5mg and 3mg Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mg and Zn (200 mg Mg and 30 mg Zn)
Study: 12200215
Drug: Extended-release divalproex
Normalized name: divalproex sodium Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release divalproex (qd)
Study: 7831492
Drug: Daily administration
Normalized name: Prevpac 30mg-500mg-500mg Daily Administration Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily administration of a stroking procedure
Study: 7831492
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of stroking procedure and multisensory hammock
Study: 2477338
Drug: Potassium hydrochloride
Normalized name: Potassium
DrugBank: Potassium (DB14500)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potassium hydrochloride 1 g twice daily
Study: 2477338
Drug: Potassium hydrochloride
Normalized name: Potassium
DrugBank: Potassium (DB14500)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potassium hydrochloride 1 g and magnesium hydroxide 500 mg twice daily
Study: 334435
Drug: Hydrochlorothiazide, 50
Normalized name: HydroCHLOROthiazide, 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide, 50 mg daily
Study: 334435
Drug: Metolazone, 5
Normalized name: Metolazone, 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metolazone, 5 mg daily
Study: 26848624
Drug: High hs-CRP
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High hs-CRP levels (≥ 13.1 mg/L)
Study: 26848624
Drug: Low hs-CRP
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low hs-CRP levels (< 13.1 mg/L)
Study: 22925817
Drug: 600 μg
Normalized name: P.G. 600 KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 μg of rectal misoprostol
Study: 22925817
Drug: 20 intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 intravenous units of oxytocin
Study: 20371660
Drug: Fenofibrate (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenofibrate (200 mg/d for 8 weeks)
Study: 20371660
Drug: Niaspan (2000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niaspan (2000 mg/d for 16 weeks)
Study: 17439513
Drug: Phloroglucinol/trimethylphloroglucinol (62.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phloroglucinol/trimethylphloroglucinol (62.2 mg P + 80 mg TMP) two pills three times daily for 7 days
Study: 16270644
Drug: Certoparin (3000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Certoparin (3000 anti-Xa IU, subcutaneously, once-daily)
Study: 16270644
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin (5000 IU, subcutaneously, three-times daily)
Study: 23563560
Drug: Chicken collagen
Normalized name: Chicken
DrugBank: Chicken (DB10519)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chicken collagen hydrolysate (CCH) 2.9 g/d
Study: 18317438
Drug: Ritonavir-boosted Atazanavir
Normalized name: atazanavir and ritonavir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritonavir-boosted Atazanavir (300/100 mg)
Study: 12649101
Drug: GM-CSF mouthwash
Normalized name: axatilimab-csfr
Approvals — FDA: no, EMA: no, PMDA: no
Description: GM-CSF mouthwash 150 micro g/day
Study: 10874052
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin (IVIg) 2 g/kg
Study: 7936832
Drug: Dexamethasone (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (0.5 mg/kg birth weight at 12-18 h of age and a second dose 12 h later)
Study: 29500968
Drug: Hypoenergetic diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypoenergetic diet high in ALA (3.4 g/d)
Study: 29500968
Drug: Control diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control diet low in ALA (0.9 g/d)
Study: 24190696
Drug: Diclofenac potassium
Normalized name: Diclofenac Potassium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac potassium (150 mg daily recommended dose, administered in three 50 mg doses across the day and evening)
Study: 23038965
Drug: High-dose daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose daunorubicin (60 mg/m2 per administration) and continuous infusion of cytarabine during the second course
Study: 23038965
Drug: High-dose HAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose HAM protocol as a second induction course
Study: 23038965
Drug: High-dose anthracycline
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose anthracycline antibiotics
Study: 21265466
Drug: Co‐Ir‐vell tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co‐Ir‐vell tablets (test formulation)
Study: 18541232
Drug: Phytoestrogen genistein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phytoestrogen genistein (54 mg/day)
Study: 8619364
Drug: Growth Hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth Hormone (GH) 25 micrograms/kg/day, n = 5
Study: 8619364
Drug: High-dose IGF-I
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose IGF-I 60 micrograms/kg b.i.d., n = 5
Study: 8619364
Drug: Low-dose IGF-I
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose IGF-I 15 micrograms/kg b.i.d., n = 6
Study: 8619364
Drug: High-dose IGF-I
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose IGF-I
Study: 8619364
Drug: Low-dose IGF-I
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose IGF-I
Study: 2248030
Drug: Tiaprofenic acid
Normalized name: tiaprofenic acid
DrugBank: Tiaprofenic acid (DB01600)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiaprofenic acid 600 mg daily for 7 days (monotherapy in 53.2% of cases)
Study: 2248030
Drug: Tiaprofenic acid
Normalized name: tiaprofenic acid
DrugBank: Tiaprofenic acid (DB01600)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiaprofenic acid 600 mg daily for 7 days (in association with antibiotics in 46.8% of cases)
Study: 7362419
Drug: Single-dose prediction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose prediction
Study: 30794429
Drug: Dairy snack
Normalized name: Beano Dairy Defense
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dairy snack (Greek yogurt, 198.9 g, 171 kcal, 0 g fat, 17 g protein)
Study: 30794429
Drug: Nondairy snack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nondairy snack (mini sandwich-type cookies, 37.5 g, 175 kcal, 7.5 g fat, 1.3 g protein)
Study: 27864713
Drug: Uncovered double
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uncovered double bare metal stent (DBS; S&G Biotech Inc.)
Study: 27864713
Drug: Uncovered single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uncovered single bare metal stent (SBSs; S&G Biotech Inc.)
Study: 19225067
Drug: Chemotherapy or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy or therapy with epidermal growth factor receptor (EGFR) inhibitors
Study: 19225067
Drug: Docetaxel therapy
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel therapy every 3 weeks
Study: 17113676
Drug: Insulin glulisine
Normalized name: Insulin Glulisine
DrugBank: Insulin glulisine (DB01309)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Insulin glulisine (0-15 min before breakfast and dinner)
Study: 17113676
Drug: Regular human
Normalized name: insulin regular human recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular human insulin (RHI) (30-45 min before breakfast and dinner)
Study: 15161783
Drug: Ragaglitazar 1
Normalized name: Ragaglitazar
DrugBank: Ragaglitazar (DB06533)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ragaglitazar 1 mg
Study: 15161783
Drug: Ragaglitazar 4
Normalized name: Ragaglitazar
DrugBank: Ragaglitazar (DB06533)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ragaglitazar 4 mg
Study: 15161783
Drug: Ragaglitazar 10
Normalized name: Ragaglitazar
DrugBank: Ragaglitazar (DB06533)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ragaglitazar 10 mg
Study: 8001939
Drug: Blood samples
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood samples for measurement of plasma zinc levels; Lavage of the vagina and ectocervix with sterile saline solution for measurement of cervicovaginal zinc levels.
Study: 3046811
Drug: Theophylline (5.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline (5.5 mg/kg administered intravenously)
Study: 26911396
Drug: 0.5 mg/0.05
Normalized name: ranibizumab 0.5 mg/0.05 mL INTRAOCULR VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/0.05 ml IVI of bevacizumab (IVB group)
Study: 26911396
Drug: 1.25 mg/0.05
Normalized name: bevacizumab 1.25 mg/0.05 mL INTRAOCULR SYRINGE (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.25 mg/0.05 ml IVI of ranibizumab (IVR group)
Study: 16282244
Drug: rhAngiostatin at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhAngiostatin at 15 mg or 60 mg twice daily in combination with carboplatin (AUC 5) and paclitaxel (175 mg/m2)
Study: 16282244
Drug: rhAngiostatin at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhAngiostatin at 15 mg or 60 mg twice daily
Study: 8714363
Drug: Cordaflex 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cordaflex 20 mg retard film coated tablets
Study: 8714363
Drug: Adalat 20
Normalized name: Adalat 20mg Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalat 20 mg retard film coated tablets
Study: 1562025
Drug: Erythropoietin (EPO)
Normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythropoietin (EPO) treatment for a mean period of 4 months
Study: 30012526
Drug: Immunotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy plus stereotactic body radiation therapy (50 Gy/4 fractions)
Study: 30012526
Drug: Immunotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy plus 45 Gy/15 fractions
Study: 30012526
Drug: Twice-daily chemoimmunoradiotherapy
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily chemoimmunoradiotherapy (45 Gy in twice-daily fractions)